

## TABLE OF CONTENTS

<b>Contents</b>	<b>Page No.</b>
Title page	(i)
Certificate supervisor	(ii)
Certificate co supervisor	(iii)
Declaration	(iv)
Copy right certificate	(v)
Acknowledgement	(vi-viii)
Table of Content	(ix-xii)
List of Tables	(xiii)
List of Figures	(xiv-xv)
List of Abbreviations	(xvi-xvii)
Abstract	(xviii-xix)
<b>Chapter -1 Introduction and Review of Literature</b>	<b>1-62</b>
1.1. Introduction	
1.1.1. Cancer epidemiology	01-03
1.1.2. Anatomy and physiology of prostate	04-05
1.1.3. Epidemiology and etiology of prostate gland	05
1.1.3.1. Age	05
1.1.3.2. Genetic background	06
1.1.3.3. Diet	06-07
1.1.3.4. Alcoholism and smoking	07
1.1.3.5. Race and ethnicity	07
1.1.3.6. Environmental factors	07
1.1.3.7. Sexual behavior	08
1.1.4. Hormonal control of prostate	08
1.1.5. Prostate cancer	09
1.1.5.1. Prostate cancer progression	09
1.1.5.2. Prostate cancer intraepithelial neoplasia	09-10
1.1.5.3 Classification of prostate cancer	10-11
1.1.5.4 Diagnosis	11

1.1.5.5 Biomarkers for early diagnosis of prostate cancer	11-12
1.1.5.6. Prostate cancer chemoprevention	12-13
1.1.5.7. Treatment	13-14
1.1.6. Diet and cancer	14
1.1.6.1. Background	14-17
1.1.6.2. Role of macronutrient in cancer	17-21
1.1.6.3. Effect of phytochemicals in cancer prevention	21-27
1.1.7. Role of flavonoid in prostate cancer	27
1.1.7.1. Definition, classification and chemistry	27-32
1.1.7.2. The epidemiology of flavonoids in cancer	32-35
1.1.7.3. Bioavailability and metabolism of flavonoids	35-39
1.1.7.4. Are flavonoid safe for human use?	39-41
1.1.8. Mechanism action of flavonoids	41
1.1.8.1. Antioxidant potential	41-45
1.1.8.2. Pre-oxidant effects	45-47
1.1.8.3 Hormonal properties	47-51
1.1.8.4. Cell cycle effects	51
1.1.8.4.1. The cell cycle - background	51-53
1.1.8.4.2. Cell cycle alteration induced by Flavonoids	53-55
1.1.8.4.3. Apoptotic effects of flavonoid treatment	56-57
1.2. Hypothesis	57-58
1.3. Aim and Objectives	58
1.4. Significance	58-59
1.5. Review of Literature	59-60
1.5.1. Plant profile of eupalitin	61
1.5.2. Plant profile of cirsilincol	62
<b>Chapter -2 Cytotoxic study of eupalitin compound</b>	<b>63-84</b>
2.1. Introduction	63-65
2.2. Materials and Methods	65
2.2.1. Chemical and reagents	65
2.2.2. Cell line and culture	65

2.2.3. Natural compound	66
2.2.4. FTIR analysis	66
2.2.5. NMR spectroscopy	66
2.2.6. Cell proliferation/viability assay	67
2.2.7. Determination of ROS activity	67-68
2.2.8. Nuclear apoptosis assay	68
2.2.9. DNA content analysis	68-69
2.2.10. Analysis of caspase -3 activity	69
2.2.11. Annexin V and PI staining for apoptosis detection	70
2.2.12. Western blot analysis	70
2.3. Results& Discussion	71
2.3.1. Structure analysis of eupalitin	71-72
2.3.2. Effect of bioactive molecule on morphological changes and anti proliferation activity	73-74
2.3.3 Intracellular ROS generation	74-75
2.3.4 Nuclear apoptosis	76-77
2.3.5. Eupalitin induces G2/M and S phase check points	77-78
2.3.6. Eupalitin increases the caspase-3 activity	78-79
2.3.7. Eupalitn induces PC3 apoptosis mediated by induction of BAX/BCL2-2 imbalance	79-81
2.3.8. Eupalitin induces apoptosis in prostate cancer cells	82-83
2.4. Conclusions	83
<b>Chapter -3 Cytotoxic study of cirsilineol compound</b>	<b>84-104</b>
3.1. Introduction	84-86
3.2. Materials and Methods	86
3.2.1. Chemical and reagents	86
3.2.2. Cell line and culture	86
3.2.3. Natural compound	86
3.2.4. FTIR analysis	87
3.2.5. NMR spectroscopy	87
3.2.6. Cell proliferation/viability assay	88
3.2.7. Determination of ROS activity	88-89

3.2.8. Nuclear apoptosis assay	89
3.2.9. DNA content analysis	89-90
3.2.10. Analysis of caspase -3 activity	90
3.2.11. Annexin V and PI staining for apoptosis detection	90-91
3.2.12. Western blot analysis	91
3.3. Results& Discussion	91
3.3.1. Spectroscopy analysis of eupalitin	91-92
3.3.2. Effect of bioactive molecule on morphological changes and anti proliferation activity	93-94
3.3.3 Intracellular ROS generation	95-96
3.3.4 Nuclear apoptosis	96-97
3.3.5. Cirsilineol induces G2/M and S phase check points	98
3.3.6. Cirsilineol increases the caspase-3 activity	99
3.3.7. Cirsilineol induces PC3 apoptosis mediated by induction of BAX/BCL2-2 imbalance	100-101
3.3.8. Cirsilineol induces apoptosis in prostate cancer cells	102-103
3.4. Conclusions	103-104
<b>Chapter -4 <i>In silico</i> docking study of eupalitin</b>	<b>105-112</b>
4.1. Introduction	105-106
4.2. Material and methods	106
4.3. Results & Discussion	106- 111
4.4. Conclusions	112
<b>Chapter -5 <i>In silico</i> docking study of cirsilineol</b>	<b>113-120</b>
5.1. Introduction	113-114
4.2. Material and methods	114
4.3. Results & Discussion	114-119
.4. Conclusions	120
Bibliography	121-163
List of publications	164
Appendices	

## LIST OF TABLES

<b>Table no.</b>	<b>Title</b>	<b>Page no.</b>
1.1.	Docking score and ADME of eupalitin and Co-crystal ligand	111
1.2.	Docking score and ADME of cirsilineol and Co-crystal ligand	119



## LIST OF FIGURES

Figure no.	Title	Page no.
1.1.	Anatomy of the male reproductive system	05
1.2.	The role of androgens testosterone and DHT action in physiological function of the prostate gland	08
1.3.	Steps involved in prostate cancer progress	09
1.4.	Gleason grading system to classify prostate cancer	11
1.5.	Sources and structure of Eupalitin	62
1.6.	Sources and structure of Cirsilineol	63
2.1.	Structure analysis of Eupalitin	72
2.2.	Morphological view of live and dead cells of PC3 cell line treated with 25 200 $\mu$ M concentration of eupalitin compound	73
2.3.	MTT assay of eupalitin against PC3 cells	74
2.4.	ROS generation assay of eupalitin against PC3 cells	74
2.5.	Chromatin condensation of PC3 cells stained with DAPI after eupalitin treatment	76
2.6.	Effect of eupalitin on different phases of the cell cycle	77
2.7.	Activation of caspase-3 by eupalitin	79
2.8.	Immunoblot analysis shows by eupalitin	80
2.9.	Eupalitin induces apoptosis in human prostate cancer cells	82
3.1.	Structure analysis of cirsilineol	92
3.2.	Morphological view of live and dead cells of PC3 cell line treated with 25, 200 $\mu$ M concentration of cirsilineol compound	93
3.3.	MTT assay of cirsilineol against PC3 cells	94
3.4.	ROS generation assay of cirsilineol against PC3 cells	95
3.5.	Chromatin condensation of PC3 cells stained with DAPI with cirsilineol	96
3.6.	Effect of cirsilineol on different phases of the cell cycle	98
3.7.	Activation of caspase-3 by cirsilineol	99
3.8.	Immunoblot analysis shows by cirsilineol	100
3.9.	Cirsilineol induces apoptosis in human prostate cancer cells	102

4.1.	2D Ligand interaction representation of Eupalitin	108
4.2.	2D Ligand interaction representation of Co-crystal ligand	108
4.3.	Docked Pose of compound Eupalitin represented as ball and stick in the binding site of androgen receptor (AR)	109
4.4.	Docked Pose of Co-crystal ligand	109
4.5.	Superimposed structure of Eupalitin (turquoise blue color) with Co-crystal	110
4.6.	Receptor surface model of Eupalitin	110
5.1.	2D Ligand interaction representation of cirsiineol	116
5.2.	2D Ligand interaction representation of Co-crystal ligand	116
5.3.	Docked Pose of compound cirsilineol represented as ball and stick in the binding site of androgen receptor (AR)	117
5.4.	Docked Pose of Co-crystal ligand	117
5.5.	Superimposed structure of cirsilineol (turquoise blue color) with Co-crystal	118
5.6	Receptor surface model of Cirsilineol represented as tube model in the binding site of androgen receptor	118







## LIST OF ABBREVIATIONS

ADME	Absorption Distribution Metabolism Excretion
AMACR	Alpha-methylacyl-CoA racemase.
AR	Androgen Receptor
ATM	Ataxia Telangectasia Mutated
BPH	Benign Prostatic Hypertrophy
CDC2	Cell Division Cell Cycle 2
CDKS	Cyclin Dependent Kinase
CHK	Checkpoint Kinase
DAPI	4', 6-Diamidino-2-Phenylindole Dihydrochloride
DCFH-DA	2, 7-Dichlorodihydrofluorescein Diacetate
DHT	Dihydrotestosterone
DMSO	Dimethyl Sulfoxide
DTT	Dithiothreitol
EGCG	Epigallocatechin Gallate
ER	Estrogen Receptor
FAS	Fatty Acid Synthase
FBS	Fetal Bovine Serum
FITC	Fluorescein Isothiocyanate
FTIR	Fourier Transforms Infrared Spectroscopy
MTT	3-(4, 5-Dimethylthiazol-2-yl)-2, 5-Diphenyltetrazolium Bromide
PBS	Phosphate Buffered Saline
PC3	Prostate Cancer Line
PCa	Prostate Cancer
PDB	Protein Data Bank

PI	Potassium Iodide
PIN	Prostatic Intraepithelial Neoplasia
PSA	Prostate Specific Antigen
RB	Retinoblastoma Protein
ROS	Reactive Oxygen Specific
UV	Ultraviolet
WCRF	World Cancer Research Fund
XP	Extra Precision
$^{13}\text{C}$ NMR	Carbon Nuclear Magnetic Resonance
$^1\text{H}$ NMR	Proton Nuclear Magnetic Resonance

## ABSTRACT

Prostate cancer is the second most common malignancy in the human reproductive system. Eupalitin is one of the O-methylated flavonol-exhibited enhanced cancer chemopreventive agents. The current study highlights anti cancer activity against prostate cancer cell line (PC3) and its underlying mechanism. Eupalitin and cirsilineol structure was determined by using FTIR, <sup>1</sup>H NMR, and <sup>13</sup>C NMR. PC3 cells were treated with increasing concentrations of eupalitin, followed by analysis of the cell viability with an MTT assay. The results demonstrated that eupalitin markedly inhibited the proliferation of PC3 cells in a concentration-dependent manner. The results from fluorescent microscopic analysis of nuclear condensation and intracellular ROS generation determined that progression as a percentage of cells in G0/G1 phase decreased whereas S phase increased. Caspase-3 immunofluorescence analysis confirms the efficacy of eupalitin-inducing apoptotic pathway and cell death. Flow cytometry analysis of Annexin V and PI stain revealed that eupalitin greatly enhanced late apoptotic cells in cells population. Molecular study using protein blot study revealed that eupalitin greatly up regulated the proapoptotic marker bax expression while down regulated the expression of antiapoptotic bcl2 protein. Furthermore, *in silico* study revealed strong binding affinity of ligand eupalitin with androgen receptors of prostate cancer. The cytotoxic response of the cancer cells to eupalitin was dose dependent. Our data indicate that eupalitin inhibits growth and induces apoptosis in human prostate carcinoma cells that may provide additional molecular targets for cancer therapy. Further spectral analysis of cirsilineol revealed the structural confirmation of the candidate. Anti proliferative study of cirsilineol revealed that ROS induction and nuclear apoptosis were enhanced slightly less than eupalitin.

Thus, our study is helpful in understanding the mechanism underlying these effects in prostate cancer and it may provide novel molecular targets for prostate cancer therapy.